The European Commission has granted EU marketing authorisation in 28 countries for Vargatef (nintedanib), from Boehringer, in combination with docetaxel...
This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are...
BMS has announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care...
Randomised controlled trial (RCT) data suggest that docetaxel (formerly Taxotere from Sanofi and now generic) improves overall survival and time...